Both healthy volunteers and patients with various acute and intensive care medical illnesses are included.
Conditions
Interventions
Group 1: Patients after liver transplantation
cfDNA measurement by qPCR and POCT on day 0 by 2 users and on day 5-7, as well as by cfDNA concentration from whole blood on day 0 and day 5-7 by one pers
Sponsors
Universitätsmedizin Mainz
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Liver transplant - Patients with intracranial hemorrhage - Infection - Sepsis - Septic shock - Patients after cardiogenic cardiac arrest and successful cardiopulmonary resuscitation) - Patients with extracorporeal heart replacement (heart-lung machine, veno-arterial extracorporeal membrane oxygenation) - Tumor disease - Rheumatological disease - Polytrauma
Exclusion criteria
Exclusion criteria: - Pregnant women - Breastfeeding women - Palliative therapy approach or therapy goal limitation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Descriptive validation isothermal Amplification method compared to the standard: 1.) Exploratory analysis of objectivity 2.) Exploratory analysis of reliability (test stability) 3.) Hypothesis-generating analysis of validity: precision and accuracy both methods (consistency) | — |
Secondary
| Measure | Time frame |
|---|---|
| Descriptive definition of: 4.) Sensitivity and specificity isothermal amplification measurement method for inflammation (C-reactive protein in patients after polytrauma) and for infection (Procalcitonin in patients with infectious diseases) 5.) Determination of the normal value range of the cfDNA concentration (POCT). Subject group 6.) Clinical study: Descriptive correlation of cfDNA values ??with parameters of the clinical course and risk factors | — |
Countries
Germany
Contacts
Public ContactKatharina Hoeter
Universitätsmedizin Mainz
Outcome results
None listed